Comparative Pharmacology
Head-to-head clinical analysis: BAL versus EDETATE CALCIUM DISODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAL versus EDETATE CALCIUM DISODIUM.
BAL vs EDETATE CALCIUM DISODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.
Chelates heavy metals (e.g., lead, cadmium) by forming stable complexes with divalent and trivalent cations, which are then excreted in urine.
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.
Edetate calcium disodium is administered intravenously or intramuscularly. For lead poisoning: 1000 mg/m²/day IV continuous infusion or in divided doses every 12 hours; alternatively 50 mg/kg/day IV or IM in divided doses every 8-12 hours. Maximum 3000 mg/day. Duration typically 5 days, repeat after 2 days rest. For other heavy metal toxicity: 50 mg/kg/day IV or IM in divided doses every 8-12 hours for 3-5 days.
None Documented
None Documented
Clinical Note
moderateBalsalazide + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Acetyldigitoxin
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Ouabain
Terminal elimination half-life is approximately 6.8 hours (range 4–13 hours). In patients with impaired renal function, half-life may be prolonged.
Terminal elimination half-life approximately 1.5-3 hours for the intact chelate; prolonged to 20-40 hours in lead-intoxicated patients due to redistribution of lead from bone.
Primarily renal; approximately 80% of a dose is excreted in urine as unchanged drug and metabolites within 24 hours. Biliary/fecal elimination accounts for less than 5%.
Primarily renal (90-100% as chelated lead complex within 24-48 hours); minimal biliary/fecal excretion (<5%).
Category C
Category C
Chelating Agent
Chelating Agent
"The serum concentration of Ouabain can be decreased when it is combined with Balsalazide."